☆ 4.6 Article

Design and Synthesis of Novel Thieno[3,2-c]quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells

ACS OMEGA (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Progress and challenges in RET-targeted cancer therapy

Xueqing Hu et al.

Summary: The rearranged during transfection (RET) is a receptor protein tyrosine kinase commonly found in non-small cell lung cancer and thyroid cancer. Two selective RET protein tyrosine kinase inhibitors, pralsetinib and selpercatinib, have been developed and approved for use. However, complete response rates to these inhibitors are low and resistance to them can occur through target mutations or alternative oncogene activation. Next-generation RET inhibitors are being tested, but the emergence of new resistance mutations remains a challenge. To address this, a better understanding of the mechanisms behind RET inhibitor tolerance is needed to develop effective co-treatment strategies.

FRONTIERS OF MEDICINE (2023)

添加到收藏夹

Article Chemistry, Medicinal

Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis

Cecilia C. Ayala-Aguilera et al.

Summary: Kinase inhibitors play a central role in the treatment of progressive disorders, with FDA approving 73 small molecule kinase inhibitor drugs by September 2021. This review summarizes the therapeutic and pharmacological properties of approved kinase inhibitors, as well as their synthesis routes, with an update on drugs approved in 2021.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antiproliferative Activity Predictor: A New Reliable In Silico Tool for Drug Response Prediction against NCI60 Panel

Annamaria Martorana et al.

Summary: In vitro antiproliferative assays play a crucial role in anticancer drug discovery, and the NCI-DTP project is a famous initiative for rapidly testing compounds against tumor cell lines. Based on the NCI database and molecular descriptors, researchers have developed the in silico Antiproliferative Activity Predictor (AAP) tool, which has proven to be highly reliable and robust. The AAP tool accurately predicts GI(50) values of compounds against the NCI60 panel.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Review Chemistry, Medicinal

Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders

Cong-Cong Jia et al.

Summary: RET is a proto-oncogene encoding a receptor tyrosine kinase, activation of which is closely related to various cancers. In the past 10 years, a variety of small molecule RET protein kinase inhibitors have been developed and classified based on their chemical types, each with different structure-activity relationships.

FUTURE MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

In Silico Identification of Small Molecules as New Cdc25 Inhibitors through the Correlation between Chemosensitivity and Protein Expression Pattern

Antonino Lauria et al.

Summary: The study identified a set of small molecules as Cdc25 modulators through a ligand-based protocol and induced-fit docking studies, leading to the discovery of new structurally heterogeneous inhibitors of Cdc25 proteins. The most active inhibitor, J3955, exhibited concentration-dependent antiproliferative activity against HepG2 cells and caused mitotic failure by G2/M-phase cell-cycle arrest, showing specific influence in cellular pathways involving Cdc25 proteins as indicated by Western blotting analysis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Chemistry, Medicinal

Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets

Antonino Lauria et al.

Summary: Quinoline is a versatile nitrogen heterocycle that can be used to develop antiproliferative agents with different mechanisms of action, such as interfering with DNA structure or proteins/enzymes. Some quinoline compounds have been studied as lead compounds for developing new agents with improved properties. Additionally, there is notable attention to quinoline molecules that interfere with emerging targets involved in cancer progression, providing possibilities for new anticancer agents.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors

Gabriele La Monica et al.

Summary: The approval of HIV-1 protease inhibitors marked an important step in AIDS treatment, but also led to severe side effects. In-silico techniques can help design new selective inhibitors with well-fitting selectivity and without undesirable interactions. This new method could be a reliable tool in the research of targeted small molecules.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Chemistry, Medicinal

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development

Debasmita Saha et al.

Summary: Aberrant signaling of RET in cancers can be effectively treated through pharmacological manipulation, and there has been an increasing focus on developing specific therapies for RET in recent years. In 2020, the first kinase inhibitors specifically developed to target the RET oncoprotein were approved, marking a significant advancement in precision medicine for RET-driven malignancies.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases

Marialuisa Moccia et al.

Summary: Pz-1 is a potent inhibitor of TRKA/B/C, with strong anti-tumor activity against cancer cells carrying RET or TRKA oncogenes. It shows distinct activity towards tumors induced by oncogenic RET and TRKA variants, including some mutants displaying resistance to other drugs, and potentially justifies its reduced effect on RET/TRKA-negative tumors through VEGFR2 inhibition.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

Tao Shen et al.

Summary: Recently FDA-approved pralsetinib and selpercatinib are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers. Selpercatinib was found to effectively inhibit certain resistant mutations that were strongly resistant to pralsetinib, showing better activity in those cases.

NPJ PRECISION ONCOLOGY (2021)

添加到收藏夹

Article Biochemical Research Methods

DRUDIT: web-based DRUgs Discovery Tools to design small molecules as modulators of biological targets

Antonino Lauria et al.

BIOINFORMATICS (2020)

添加到收藏夹

Article Chemistry, Medicinal

Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma

Casey J. N. Mathison et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Update on Fundamental Mechanisms of Thyroid Cancer

Alessandro Prete et al.

FRONTIERS IN ENDOCRINOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy

Maria San Roman Gil et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Review Cell Biology

Intracellular RET signaling pathways activated by GDNF

Kumi Kawai et al.

CELL AND TISSUE RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways

Annamaria Martorana et al.

MOLECULES (2020)

添加到收藏夹

Article Biochemical Research Methods

Design of antitumor drugs targeting c-kit receptor by a new mixed ligand-structure based method

Annamaria Martorana et al.

JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2020)

添加到收藏夹

Review Oncology

RET kinase alterations in targeted cancer therapy

Xuan Liu et al.

CANCER DRUG RESISTANCE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib

Simon S. Terzyan et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

添加到收藏夹

Article Biology

Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands

Jie Li et al.

eLife (2019)

添加到收藏夹

Review Genetics & Heredity

Influencers on Thyroid Cancer Onset: Molecular Genetic Basis

Berta Luzon-Toro et al.

GENES (2019)

添加到收藏夹

Article Oncology

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Alexander Drilon et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors

Valeria La Pietra et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers

Robert Roskoski et al.

PHARMACOLOGICAL RESEARCH (2018)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS

Hilary Schenck Eidam et al.

ACS MEDICINAL CHEMISTRY LETTERS (2018)

添加到收藏夹

Article Oncology

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

Gang G. Li et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Chemistry, Medicinal

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor

Hojong Yoon et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer

Julien Hadoux et al.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2017)

添加到收藏夹

Article Endocrinology & Metabolism

The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer

Valentina De Falco et al.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2017)

添加到收藏夹

Article Chemistry, Medicinal

Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors

Chengyan Wang et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)

添加到收藏夹

Article Chemistry, Medicinal

A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants

Hojong Yoon et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Chemistry, Medicinal

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position

Allan M. Jordan et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)

添加到收藏夹

Article Chemistry, Medicinal

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity

Rebecca Newton et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Chemistry, Medicinal

Multivariate analysis in the identification of biological targets for designed molecular structures: The BIOTA protocol

Antonino Lauria et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)

添加到收藏夹

Review Oncology

RET revisited: expanding the oncogenic portfolio

Lois M. Mulligan

NATURE REVIEWS CANCER (2014)

添加到收藏夹

Review Oncology

Sorafenib and Thyroid Cancer

Poupak Fallahi et al.

BIODRUGS (2013)

添加到收藏夹

Article Oncology

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Kiyoshi Okamoto et al.

CANCER LETTERS (2013)

添加到收藏夹

Article Chemistry, Medicinal

New annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with potent anticancer activity, designed through VLAK protocol

Antonino Lauria et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Review Pharmacology & Pharmacy

RET inhibition: implications in cancer therapy

Maria Grazia Borrello et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2013)

添加到收藏夹

Article Chemistry, Medicinal

Synthesis and Biological Activities of a New Class of Heat Shock Protein 90 Inhibitors, Designed by Energy-Based Pharmacophore Virtual Screening

Antonino Lauria et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Cell Biology

Structure and Physiology of the RET Receptor Tyrosine Kinase

Carlos F. Ibanez

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)

添加到收藏夹

Article Chemistry, Medicinal

Lead optimization through VLAK protocol: New annelated pyrrolo-pyrimidine derivatives as antitumor agents

Antonino Lauria et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)

添加到收藏夹

Article Chemistry, Medicinal

Preparation of 3-Substituted-1-Isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET Kinase Inhibitors

Peter Diner et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

添加到收藏夹

Article Chemistry, Medicinal

Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E

Martin W. Rowbottom et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors

Luca Mologni et al.

BIOORGANIC & MEDICINAL CHEMISTRY (2010)

添加到收藏夹

Article Chemistry, Medicinal

Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl) nicotinonitrile scaffold

Wiebke Brandt et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)

添加到收藏夹

Article Oncology

Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance

D. Engelmann et al.

ENDOCRINE-RELATED CANCER (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure and chemical inhibition of the RET tyrosine kinase domain

Phillip P. Knowles et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

添加到收藏夹

Article Biochemical Research Methods

Analysis of apoptosis by propidium iodide staining and flow cytometry

Carlo Riccardi et al.

NATURE PROTOCOLS (2006)

添加到收藏夹

Article Chemistry, Medicinal

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)

A Wissner et al.

JOURNAL OF MEDICINAL CHEMISTRY (2003)

添加到收藏夹

Review Multidisciplinary Sciences

Oncogenic kinase signalling

P Blume-Jensen et al.

NATURE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.